

## RESEARCH ARTICLE

## Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients

Ruben Smith<sup>1,2</sup> | Nicholas C. Cullen<sup>1</sup> | Alexa Pichet Binette<sup>1</sup> | Antoine Leuzy<sup>1</sup> |  
 Kaj Blennow<sup>3,4</sup> | Henrik Zetterberg<sup>3,4,5,6,7</sup> | Gregory Klein<sup>8</sup> | Edilio Borroni<sup>8</sup> |  
 Rik Ossenkoppele<sup>1,9</sup> | Shorena Janelidze<sup>1</sup> | Sebastian Palmqvist<sup>1,10</sup> |  
 Niklas Mattsson-Carlsson<sup>1,2,11</sup> | Erik Stomrud<sup>1,10</sup> | Oskar Hansson<sup>1,10</sup> | for the  
 Alzheimer's Disease Neuroimaging Initiative\*

<sup>1</sup>Department of Clinical Sciences, Clinical Memory Research Unit, Malmö, Lund University, Lund, Sweden<sup>2</sup>Department of Neurology, Skåne University Hospital, Lund, Sweden<sup>3</sup>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden<sup>4</sup>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden<sup>5</sup>Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK<sup>6</sup>UK Dementia Research Institute at UCL, London, UK<sup>7</sup>Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China<sup>8</sup>F. Hoffmann-La Roche Ltd., Basel, Switzerland<sup>9</sup>Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands<sup>10</sup>Memory Clinic, Skåne University Hospital, Malmö, Sweden<sup>11</sup>Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden

## Correspondence

Oskar Hansson, Memory Clinic, Skåne University Hospital SE-205 02, Malmö, Sweden.  
 Email: [Oskar.Hansson@med.lu.se](mailto:Oskar.Hansson@med.lu.se)

\* Part of the data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

## Funding information

Swedish Research Council, Grant/Award Number: 2016-00906; Knut and Alice

## Abstract

**Introduction:** Biomarkers for the prediction of cognitive decline in patients with amnesic mild cognitive impairment (MCI) and amnesic mild dementia are needed for both clinical practice and clinical trials.

**Methods:** We evaluated the ability of tau-PET (positron emission tomography), cortical atrophy on magnetic resonance imaging (MRI), baseline cognition, apolipoprotein E gene (APOE) status, plasma and cerebrospinal fluid (CSF) levels of phosphorylated tau-217, neurofilament light (NfL), and amyloid beta (A $\beta$ )<sub>42/40</sub> ratio (individually and in combination) to predict cognitive decline over 2 years in BioFINDER-2 and Alzheimer's Disease Neuroimaging Initiative (ADNI).

**Results:** Baseline tau-PET and a composite baseline cognitive score were the strongest independent predictors of cognitive decline. Cortical thickness and NfL provided some additional information. Using a predictive algorithm to enrich patient selection in a theoretical clinical trial led to a significantly lower required sample size.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Wallenberg Foundation, Grant/Award Number: 2017-0383; Marianne and Marcus Wallenberg Foundation, Grant/Award Number: 2015.0125; Swedish Alzheimer Foundation, Grant/Award Numbers: AF-939932, AF-939981; Swedish Brain Foundation, Grant/Award Number: FO2019-0326; Parkinson Foundation of Sweden, Grant/Award Number: 1280/20; Skåne University Hospital Foundation, Grant/Award Number: 2020-0000028; Regionalt Forskningsstöd, Grant/Award Number: 2020-0314; Swedish Federal Government, Grant/Award Number: 2018-Projekt0279; European Research Council, Grant/Award Number: #681712; Swedish State Support for Clinical Research, Grant/Award Number: #ALFGBG-720931; Alzheimer's Drug Discovery Foundation (ADDF), Grant/Award Number: #201809-2016862; AD Strategic Fund and the Alzheimer's Association, Grant/Award Numbers: #ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C; Olav Thon Foundation; Erling-Persson Family Foundation; Stiftelsen för Gamla Tjänarinnor, Grant/Award Number: #FO2019-0228; Marie Skłodowska-Curie, Grant/Award Number: 860197; Alzheimer's Drug Discovery Foundation (ADDF), Grant/Award Number: #RDAPB-201809-2016615; Swedish Alzheimer Foundation, Grant/Award Number: #AF-742881; Swedish Government and the County Councils, Grant/Award Number: #ALFGBG-715986; European Union Joint Program for Neurodegenerative Disorders, Grant/Award Number: JPND2019-466-236; National Institutes of Health, Grant/Award Numbers: #1R01AG068398-01, U01 AG024904; Department of Defense, Grant/Award Number: W81XWH-12-2-0012

**Discussion:** Models including baseline tau-PET and cognition consistently provided the best prediction of change in cognitive function over 2 years in patients with amnesic MCI or mild dementia.

#### KEYWORDS

AD, blood biomarkers, cognition, PET, tau

## 1 | INTRODUCTION

Amyloid beta ( $A\beta$ ) plaques and tau tangles are the pathologies that define Alzheimer's disease (AD).<sup>1</sup> Cerebrospinal fluid (CSF)  $A\beta$  was shown to be associated with an increased risk of progression from mild cognitive impairment (MCI) to AD dementia already 20 years ago,<sup>1-3</sup> and the first positron emission tomography (PET) tracer for  $A\beta$  was developed shortly thereafter.<sup>4</sup> More recently, methods to accurately measure  $A\beta$  in plasma have been developed.<sup>1,5-7</sup> Over the past several years, new methods have been developed to visualize tau pathology in vivo using tau-PET imaging<sup>8</sup> and to determine levels of phosphorylated tau (p-tau) in CSF<sup>9,10</sup> and plasma.<sup>1,11-16</sup> The rapid development of tau-PET tracers has led to the recent approval by the US Food and Drug Administration (FDA) of [<sup>18</sup>F]florbetapir as a diagnostic agent in AD dementia.<sup>17</sup> Tau-PET has been shown to reliably detect the tau aggregates formed in AD,<sup>18,19</sup> and shows strong associations with both cognitive decline<sup>20-24</sup> and neurodegeneration.<sup>25,26</sup> Levels of p-tau in CSF and plasma have been shown to begin increasing at the asymptomatic (preclinical) stage of AD in response to

very early  $A\beta$  pathology.<sup>27-30</sup> Higher baseline concentrations of p-tau have also been shown to accurately predict progression to AD dementia in both cognitively unimpaired (CU) individuals and in patients with MCI.<sup>12,31-33</sup> Neurofilament light (NfL), a more general marker of neurodegeneration, has been reported to be increased in AD,<sup>34</sup> and to be associated with conversion from MCI to AD dementia.<sup>32</sup>

As mentioned in the preceding text, we and others have recently shown that blood-based biomarkers of  $A\beta$  (A), tau (T), and neurodegeneration (N) can predict both future cognitive decline and conversion to AD dementia.<sup>11-16,31-33</sup> Furthermore, tau-PET has also been shown to be an important predictor of cognitive decline in AD.<sup>26,35,36</sup> However, there is a clear lack of head-to-head comparisons of these type of promising fluid and imaging biomarkers, and there is also an urgent need to determine the optimal biomarker combinations for the prediction of cognitive decline in patients with MCI or mild dementia over a clinically relevant time span such as 24 months. This information is of great importance both in clinical settings to establish the risk of cognitive decline in symptomatic patients at a subject level, and in

the settings of clinical trials directed against symptomatic AD where follow-up time typically ranges between 18 and 24 months.<sup>37–39</sup>

We, therefore, aimed to determine the ability of different blood and CSF, as well as imaging ATN biomarkers associated with AD, to independently predict cognitive decline in patients with objective memory impairment. To this end, we analyzed the ability of (1) the most relevant plasma and CSF biomarkers (i.e., p-tau217, NfL, and the ratio of A $\beta$ 42 to A $\beta$ 40 [A $\beta$ <sub>42/40</sub>]), (2) tau-PET ([<sup>18</sup>F]RO948 standardized uptake value ratios [SUVRs]) in three different regions of interest (ROIs); (3) baseline cognition; (4) magnetic resonance imaging (MRI; cortical thickness in an “AD-signature” temporal-ROI<sup>40</sup>); and (5) the main genetic risk variant for sporadic AD (the apolipoprotein E (APOE)  $\epsilon$ 4 allele), to predict longitudinal cognitive performance over 2 years in patients presenting with amnesic MCI or amnesic mild dementia. We included patients with amnesic MCI or mild amnesic dementia without requiring them to already have evidence of A $\beta$  pathology (defined by CSF or PET) to be able to identify which markers best predict cognitive decline independent of A $\beta$  status. This is a relevant situation in clinical practice, where most patients with amnesic memory impairment have an unknown A $\beta$  status. In a sensitivity analysis we restricted the participants to only include A $\beta$ -positive participants to mimic a clinical trial setting. Based on the main results presented in this study, including all participants, we have developed a prototype of an online prognostic tool that can be used to predict cognitive decline over 24 months, either to provide individualized prognostic information in clinic practice or when recruiting suitable participants to clinical trials. It is important to note that the main results were replicated in an independent cohort (Alzheimer's Disease Neuroimaging Initiative [ADNI]).

## 2 | METHODS

### 2.1 | Participants

We included participants from the Swedish BioFINDER-2 study ( $n = 118$ ; May 2017–March 2021; [www.biofinder.se](http://www.biofinder.se)). The inclusion criteria for the present study were (1) either amnesic MCI ( $n = 90$ ) or early amnesic dementia ( $n = 28$ ) and (2) a baseline Mini-Mental State Examination (MMSE) score of  $\geq 22$  points; and (3) a complete data set for all studied biomarkers. In addition to presenting with amnesic memory problems patients with MCI, either fulfilled established Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) clinical criteria for mild neurocognitive disorder, or met the DSM-5 criteria for major neurocognitive disorder possibly due to AD.

BioFINDER-2 participants underwent a medical history and neurological examination, brain MRI, blood and CSF sampling, [<sup>18</sup>F]RO948 tau-PET, and repeated neuropsychological testing after 1, 2, and 3 years. Only participants with cognitive follow-up data extending over  $\geq 2$  years were included in the analysis, but results from all available time points were used for cognitive slope calculation. At baseline, participants also underwent a cognitive battery including Trail Making Test Parts A and B (TMT-A, TMT-B), animal fluency (AF), and the wordlist delayed recall part of the Alzheimer's Disease Assessment

### RESEARCH IN CONTEXT

- Systematic review:** We reviewed the literature regarding biomarkers and subsequent cognitive decline in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia. Many individual biofluid and imaging biomarkers have been shown to be able to predict future cognitive decline. However, a comprehensive head-to-head study of the individual contribution of the most relevant biomarkers, such as tau-PET (positron emission tomography) and plasma phosphorylated tau (p-tau), is lacking.
- Interpretation:** The biomarker exhibiting the best independent prediction of cognitive decline in patients with amnesic MCI or amnesic dementia was tau-PET followed by baseline cognition. The results imply that tau-PET might be an important addition to the diagnostic work-up of AD in clinical practice and trials when prognostic information is of importance.
- Future directions:** Even though the results were very similar between BioFINDER-2 (single-center study in Sweden) and Alzheimer's Disease Neuroimaging Initiative (ADNI; multi-center study in the United States), further studies need to validate the results in more diverse study populations.

Scale-cognitive subscale (ADAS-cog). These tests were used to calculate a baseline cognitive composite score by computing z-scores based on the means and standard deviations of CU participants ( $n = 465$ ) from the BioFINDER2 study. The baseline cognitive composite was calculated as  $-ADAS-cog_{z-score} + -TMT-B_{z-score} + AF_{z-score}$ . These three cognitive tests were used in combination because they were shown to be the best predictors of conversion to AD dementia.<sup>33</sup> For a sensitivity analysis using a modified Preclinical Alzheimer Cognitive Composite (PACC) as an outcome we calculated modified PACC z-scores using the formula:  $MMSE_{z-score} + 2 \times (-ADAS-cog_{z-score}) + -TMT-A_{z-score} + AF_{z-score}$ . TMT-A was used instead of TMT-B in the longitudinal analysis to minimize the loss of AD participants at follow-up visits. Written informed consent was obtained from all participants prior to entering the study and the study was approved by the regional review board for human research ethics at Lund University. Details on ADNI participants are provided in the Supplemental Information.

### 2.2 | Image acquisition, processing, and biofluid biomarker collection and processing

Image acquisition and processing as well as biofluid biomarker handling are described in detail in the Supplementary Information. In an initial analysis we found that Braak III/IV was the best predictor

(highest *t*-value) of cognitive decline of these three meta-ROIs, and consequently only the Braak III/IV (temporal ROI) region was used in further analyses, to avoid multiple, dependent tau-PET predictors (Table S1).

## 2.3 | Statistics

Linear regression modeling was used to predict change in cognition, with each biomarker measured separately as the main predictor and in combination. Age, sex, education, and baseline MMSE were included as covariates. Change in MMSE (slope) was calculated for each individual as the slope of a linear regression based on all available follow-up visits. Only individuals who had all available biomarker measurements were included in order to ensure direct comparability of model results. Models were evaluated using *t*-values,  $R^2$ , and change in Akaike information criterion (AIC) values. A model with an AIC value more than two points lower than another model can be considered significantly different.<sup>32</sup> To find the most parsimonious model that could predict cognitive decline we performed an initial selection using the R package MuMIn, which tests all possible variable combinations and then ranks the models according to their AIC.<sup>41</sup> As a complementary model, stepwise removal of the variable with the highest *p*-value from the full model was performed and the model with the lowest AIC was considered as the optimal model with the best tradeoff between model fit and complexity. The parsimonious model selected was the model with the fewest predictors within two AIC points from the optimal model. Note that before starting the analyses, to limit the number of biomarkers studied and minimize the risk of random false-positive findings, we selected biomarkers shown in previous studies to be associated with cognitive decline in AD. To avoid collinearity due to dependent predictors (such as for example p-tau measured in CSF and plasma), and since in clinical practice or clinical trial settings often blood, but not CSF, is sampled, we performed the analysis of plasma and CSF biomarkers separately.

Finally, we performed a simulated clinical trial power analysis in which the ability of each measure to increase trial power was determined when used for inclusion screening. First, the number of trial participants needed to achieve 80% power to detect a reduction in cognitive change was calculated for each group without any additional inclusion criteria ("unenriched scenario"). Next, the same calculation was performed when assuming that only individuals in the 25%, 30%, 35%, etc., top percentile of risk for cognitive decline as predicted by the parsimonious model would be included in the trial ("enriched scenario"). The percent difference in number of trial participants needed between the unenriched and enriched scenarios was then reported along with *p*-values based on the proportion of 1000 bootstrap trials in which the enriched scenario required fewer participants than the unenriched scenario. All statistical tests were two tailed with a significance level of 0.05. All analyses were performed using the R programming language (v 4.0).

**TABLE 1** Demographic information

	Participants
<i>n</i>	118
Sex (F/M)	57/61
Age (years ± SD)	71.0 ± 8.6
Education (years ± SD)	12.8 ± 4.4
Baseline MMSE (mean ± SD)	26.4 ± 2.4
MMSE slope (mean ± SD)	−1.40 ± 1.92
mPACC slope (mean ± SD) <sup>a</sup>	−1.30 ± 2.67
Cognitive baseline z-score (mean ± SD)	−6.3 ± 3.2
[ <sup>18</sup> F]RO948 temporal SUVR (mean ± SD)	1.47 ± 0.47
Plasma p-tau217 (ng/mL; mean ± SD)	3.97 ± 5.02
Plasma NfL (ng/mL; mean ± SD)	21.2 ± 24.4
Plasma Aβ <sub>42/40</sub> ratio (mean ± SD)	0.21 ± 0.04
CSF p-tau217 (ng/mL; mean ± SD)	278 ± 286
CSF NfL (ng/mL; mean ± SD)	234 ± 182
CSF Aβ <sub>42/40</sub> ratio (mean ± SD)	0.07 ± 0.03
Aβ positive (%)	77/118 (65)

Abbreviations: CSF, cerebrospinal fluid; F, female; M, male; mL, milliliter; MMSE, Mini-Mental State Examination; mPACC, modified Preclinical Alzheimer Cognitive Composite; *n*, number; NfL, Neurofilament Light chain; ng, nanogram; SD, standard deviation; SUVR, standardized uptake value ratio.

<sup>a</sup>Modified PACC measurement used for a sensitivity analysis (*n* = 103).


## 3 | RESULTS

### Participants and biomarkers

A total of 118 participants presenting with memory impairment (either amnesic MCI or amnesic mild AD dementia) from the Swedish BioFINDER-2 study were included in the study. The mean age ± SD was 71.0 ± 8.6 years, mean education duration was 12.8 ± 4.4 years, 48% of participants were female, and the mean baseline MMSE was 26.4 ± 2.4 (range 22–30). Participant demographics for the included cohort are provided in Table 1. MMSE scores were obtained at baseline and at annual follow-up for up to 3 years. Cognitive decline was computed as the change (slope) in MMSE score per year and correlated to 10 biomarkers: plasma and CSF p-tau217, plasma and CSF NfL, plasma and CSF Aβ<sub>42/40</sub> ratio, tau-PET SUVR in a temporal ROI (corresponding to Braak imaging stages III–IV), APOE ε4 status, cortical thickness in "AD-signature" cortex, and the cognitive baseline composite score.

### Prediction of cognitive decline by individual biomarkers

We found that baseline tau-PET SUVR in the temporal ROI showed the highest *t*-values,  $R^2$ , and lowest AIC values, when each biomarker was



**FIGURE 1** Prediction of cognitive decline using biomarkers individually or in combination. The figure shows the effect sizes for each biomarker in predicting future cognitive decline either alone (orange bars, on top) or in a combined model (black bars, below). Significant biomarkers are represented with a star. The model using cerebrospinal fluid (CSF) biomarkers is shown in the left panel and the model using plasma biomarkers in the right panel. Bars represent 95% confidence intervals

used individually to predict change in cognition ( $t = -6.26$ ,  $R^2 = 0.33$ ,  $\Delta AIC = -33$  compared to a model including only the covariates; Figure 1 and Tables S2 and S3). Baseline cognition, cortical atrophy, CSF NfL, and plasma and CSF p-tau217 also individually significantly predicted cognitive decline (Figure 1, Tables S2 and S3). As expected, models including all biomarkers provided better model fit (higher  $R^2$ -values). They also provided better  $\Delta AIC$  values as compared to the best single predictor tau-PET (Tables S2 and S3).

### Prediction of cognitive decline by biomarker combinations

We next determined the most parsimonious model that could provide a non-inferior prediction of future cognitive decline compared to the full models combining all predictors. We, therefore, sequentially removed one biomarker at a time from the full model in a step-wise fashion (the biomarker with the highest  $p$ -value in the model was removed) and refit the model. Data showing the change in AIC and  $R^2$  upon biomarker removal are presented in Table 2. The combination of tau-PET, baseline cognition, cortical atrophy, and NfL provided the most parsimonious models (with the fewest number of predictors, and AIC within  $<2$  from the model with the lowest AIC), where tau-PET and baseline cognition were the strongest predictors (Table 2). We next confirmed this model using an automated data-driven model selection (MuMin) to evaluate the ability of all possible biomarker combinations to predict cognitive decline. Again we found that for both plasma and CSF analyses, the combination of tau-PET, cortical atrophy, NfL, and baseline cognition provided the lowest AICs.

In a sensitivity analysis, when restricting the analysis to only amnesic MCI participants ( $n = 90$ ), we found similar results (Table S4).

Furthermore, when including only participants that were A $\beta$  positive (Table S5) to mimic the scenario of a clinical trial, tau-PET and baseline cognition were significant predictors, whereas NfL and cortical atrophy were no longer significant predictors. Finally, when using change in modified PACC over time as the cognitive outcome (instead of change in MMSE), we again found that tau-PET and baseline cognition were the strongest predictors of cognitive decline in the parsimonious models, but with minor contributions from plasma NfL and plasma p-tau217 (Table S6). In another sensitivity analysis we found no added value of plasma or CSF glial fibrillary acidic protein (GFAP) or CSF levels of the synaptic marker neurogranin in the BioFINDER cohort (data not shown).

To validate our findings we included 50 participants from the ADNI cohort having a complete set of biomarkers for age, sex, education, baseline and longitudinal MMSE, baseline cognition, tau-PET ( $[^{18}F]$ flortaucipir), APOE  $\epsilon 4$  status, A $\beta$  status, plasma NfL, plasma p-tau181, and cortical thickness. We found that tau-PET and baseline cognition were again the best predictors of longitudinal cognitive decline, but plasma NfL and cortical atrophy did not contribute to the model (Table S7).

### Enrichment of clinical trials using biomarkers

With the aim of studying the importance of screening biomarker data for clinical trial design we next calculated the impact of biomarker enrichment on group sizes needed to achieve a preset statistical power of 80%. We found that using the parsimonious models defined in BioFINDER-2—that is, tau-PET, baseline cognition, NfL, and cortical thickness—to enrich for higher risk of cognitive decline resulted in significant reduction in group sizes with preserved statistical power




**TABLE 2** Selection of the most parsimonious model for predicting cognitive decline in patients with amnesic MCI and amnesic mild dementia

Model	Plasma p-tau217	APOE ε4 status	Plasma Aβ ratio	Plasma NfL	MR AD cortex	Baseline cognition	tau-PET	R <sup>2</sup>	p-value	AIC
Full plasma model	−0.11 (0.91)	0.38 (0.71)	0.54 (0.59)	−1.85 (0.07)	2.43 (0.02)	3.27 (0.001)	−4.89 (<0.0001)	0.44	<0.0001	108
Plasma model -1	−	0.37 (0.71)	0.54 (0.59)	−1.87 (0.06)	2.48 (0.01)	3.28 (0.001)	−5.30 (<0.0001)	0.44	<0.0001	106
Plasma model -2	−	−	0.41 (0.68)	−1.99 (0.05)	2.47 (0.02)	3.27 (0.001)	−5.34 (<0.0001)	0.44	<0.0001	104
Plasma model -3	−	−	−	−2.02 (0.046)	2.48 (0.01)	3.29 (0.001)	−5.49 (<0.0001)	0.44	<0.0001	103
Plasma model -4	−	−	−	−	2.36 (0.02)	3.19 (0.002)	−5.59 (<0.0001)	0.42	<0.0001	105
Plasma model -5	−	−	−	−	−	3.18 (0.002)	−6.08 (<0.0001)	0.39	<0.0001	109
Plasma model -6	−	−	−	−	−	−	−6.26 (<0.0001)	0.33	<0.0001	117

Model	CSF p-tau217	APOE ε4 status	CSF Aβ ratio	MR AD cortex	CSF NfL	Baseline cognition	tau-PET	R <sup>2</sup>	p-value	AIC
Full CSF model	0.22 (0.82)	−0.67 (0.51)	−1.16 (0.25)	2.56 (0.01)	−2.90 (0.005)	3.13 (0.002)	−4.27 (<0.0001)	0.47	<0.0001	102
CSF model -1	−	−0.69 (0.49)	−1.32 (0.19)	2.59 (0.01)	−2.91 (0.004)	3.13 (0.002)	−5.26 (<0.0001)	0.47	<0.0001	100
CSF model -2	−	−	−1.13 (0.26)	2.66 (0.009)	−2.84 (0.005)	3.17 (0.002)	−5.32 (<0.0001)	0.47	<0.0001	98.8
CSF model -3	−	−	−	2.70 (0.008)	−2.90 (0.005)	3.04 (0.003)	−5.29 (<0.0001)	0.46	<0.0001	98.2
CSF model -4	−	−	−	−	−2.58 (0.01)	3.04 (0.003)	−5.85 (<0.0001)	0.42	<0.0001	104
CSF model -5	−	−	−	−	−	3.18 (0.002)	−6.08 (<0.0001)	0.39	<0.0001	109
CSF model -6	−	−	−	−	−	−	−6.26 (<0.0001)	0.33	<0.0001	117

Note: Results from the stepwise regression model. The variable with the highest p-value was removed from the model and the R<sup>2</sup> and AIC of the new model were assessed. For both plasma and CSF analyses the lowest AIC was achieved with models containing [18F]RO948 (tau-PET), MR cortical thickness, neurofilament light (NfL), and baseline cognitive data (models highlighted with light orange). All models included sex, education, age, and baseline MMSE as covariates. tau-PET = [18F]RO948 standardized uptake ratio values in a temporal ROI; MR AD cortex = Cortical thickness in “AD signature cortex” (see Methods for details); Aβ ratio = Aβ<sub>42/40</sub> ratio. Biomarker values indicate t-values (p-values).



**FIGURE 2** Enrichment for clinical trials using the parsimonious model biomarkers. The top panel of the graph shows the effect on group size needed to include in a clinical trial to retain statistical power when enriching for pathological values for the tau-PET (positron emission tomography), baseline cognition, cortical thickness, and neurofilament light (NfL) biomarkers (cerebrospinal fluid [CSF] NfL in black; plasma NfL in orange). The bottom panel shows the rate of amyloid beta ( $A\beta$ ) positivity with the different inclusion thresholds (CSF in black; plasma in orange)

(Figures 2 and S1; full details provided in Table S8). These results are independent of the assumed treatment effect. There were no statistically significant differences in the reduced group sizes between using CSF and plasma biomarkers (Figure S1). The results indicated that restricting inclusion to the 50% of participants with the highest predicted risk for cognitive decline resulted in a need for  $\approx 52\%$  fewer participants compared to having no enrichment strategy (Figure 2). Biomarker enrichment further resulted in removal of  $A\beta$ -negative individuals, even if  $A\beta$  biomarkers were not used in the parsimonious selection model. For example, in an unselected population, 65% of amnesic individuals were  $A\beta$  positive, compared to  $\approx 80\%$  using a 75% cutoff (i.e., including the 75% with the most pathological values, and excluding the 25% with most normal values), 92%–93% using a 50% cutoff, and 97% using a 25% cutoff. In a sensitivity analysis, a simpler model containing only the most important predictors (i.e., tau-PET and cognition) performed similarly as the full models for study enrichment (Figure S2).

### Generation of a prediction algorithm for future cognitive decline


To simplify the use of the data provided herein we have generated a web-based application for calculating the risk of cognitive decline over a 2-year period, based on the full BioFINDER2 data set. The web-application is available at: <https://brainapps.shinyapps.io/PredictMMSE> (Figure 3).

## 4 | DISCUSSION

Plasma,<sup>12,33</sup> CSF,<sup>42,43</sup> and imaging biomarkers<sup>35,36,42–48</sup> of A, T, and N have been used previously individually or in combination to predict cognitive decline and conversion to AD dementia. However, a comprehensive direct head-to-head comparison of the relative contributions of plasma, CSF, and tau-PET biomarkers to the prediction of cognitive decline is lacking. To address this gap and to allow direct comparisons of the relative contribution of the different biomarkers to the prediction, we used a data set where data for all studied biomarkers were available in all participants. In short, we found that models consisting of tau-PET and baseline cognition were most strongly and consistently associated with subsequent cognitive decline in a heterogeneous population of patients with amnesic MCI or mild amnesic dementia. Furthermore, there were more modest and more variable contributions of NfL and cortical thickness, but plasma (or CSF) p-tau, plasma (or CSF)  $A\beta_{42/40}$ , and APOE  $\epsilon 4$  status were not included in the main models.

The present results are in line with a recent study showing that tau-PET is superior to  $A\beta$ -PET and MRI when predicting subsequent cognitive change in AD,<sup>35</sup> but in that large multicenter cohort plasma biomarkers, CSF biomarkers, and baseline cognition were not studied.

The present finding that NfL and cortical atrophy provides modest, but independent, information compared to tau-PET alone might be expected, considering that NfL and cortical atrophy reflect ongoing axonal degeneration and substance loss of the brain, which is clearly different from the tau aggregates detected with tau-PET imaging.<sup>1</sup> Previous studies have suggested a role for structural cortical volumetric or



**FIGURE 3** Prediction algorithm for cognitive decline. Example of the implementation of the regression models at <https://brainapps.shinyapps.io/PredictMMSE/>. At this website it is possible to enter basic demographic data (age, sex, and education), biomarker data (tau-PET temporal Region-of-interest (ROI) Standardized Uptake Value Ratio (SUVR) and plasma Neurofilament Light (NfL) [pg/mL]) as well as raw cognitive test scores (Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale (ADAS) delayed recall, Trail-making test-B (TMT-B), and animal fluency). The example shows the predicted individual change in cognition for a 70-year-old woman who has 14 years of education, a pathological tau-PET (2.44 SUVR), a plasma NfL of 4.5 pg/mL, and a cortical thickness of 2.3 mm (please note that entering cortical thickness is optional). She has a baseline MMSE score of 27, scores seven errors on a 10-word delayed-recall test, completes the Trail-Making Test B in 124 s, and names 12 animals in 1 min

thickness MRI measures<sup>43,45,48,49</sup> in the prediction of cognitive decline in AD. Cross-sectionally we and others have reported that temporal cortical atrophy on MRI and increased tau-PET uptake are associated with a worse cognitive performance.<sup>42,44,46,47,50</sup> However, neither NfL nor cortical atrophy was a significant predictor in the ADNI validation cohort, possibly reflecting the smaller sample size and potentially also the lower number of early AD dementia participants in the ADNI data set (Table S9).

Plasma (or CSF) p-tau was not selected in the main parsimonious models most likely because this biomarker, similar to  $A\beta_{42/40}$  and  $A\beta$ -PET, becomes abnormal much earlier than tau-PET, and in the case of  $A\beta_{42/40}$  likely already 10–30 years before onset of objective memory impairment.<sup>1,11,15</sup> Tau-PET is more closely related to neurodegeneration and cognitive decline during the symptomatic stages of AD,<sup>1,35</sup> likely explaining why we found that plasma (and CSF) p-tau do not seem to contribute with independent information beyond tau-PET in



patients with MCI and mild dementia. CSF p-tau217 level was pathological in 60% of participants at baseline (including all AD-dementia participants). In comparison, 38% of participants had a pathological RO948 PET at baseline. That said, plasma p-tau might be more useful during preclinical stages of AD, where it can predict future increase in tau-PET uptake.<sup>51</sup>

Furthermore, baseline cognition (here evaluated using composites of memory and executive function) showed an association with future cognitive decline, even after adjusting for baseline MMSE, but performed significantly inferior compared to the parsimonious model or tau-PET when used alone (Table 2, Tables S2 and S3). Still, inclusion of baseline cognition added independent information to the parsimonious models on top of tau-PET, cortical thickness, and NFL data, showing the value of brief cognitive testing in the clinic when predicting subsequent cognitive decline. Similarly, we have previously found that the same three cognitive tests together with plasma p-tau can predict conversion to AD dementia in patients with subjective cognitive decline (SCD) or MCI, but again tau-PET was not available in that study.<sup>33</sup>

Conducting clinical studies is very expensive because large populations need to be included to have a sufficient number of progressors over a relatively short time interval to show an effect of the treatment. In an unselected population, only a minority of patients with MCI or mild dementia will progress significantly over a 2-year period. Optimizing the trial design by selecting patients who are more likely to progress is therefore of great importance for reducing the number of required participants. We consequently aimed to see whether preselecting study participants for a theoretical clinical trial based on their baseline biomarker levels could reduce the number of required participants without compromising statistical power. Restricting the study population using the parsimonious model to more pathological biomarker values resulted in a significant reduction in sample sizes needed (Figure 2; Table S8 and Figure S1). It is important to note that for the use of these biomarkers in the selection of participants for future clinical studies of AD, selection based on the parsimonious model including only tau-PET, baseline cognition, cortical atrophy, and NFL also selected for A $\beta$  positivity, thereby decreasing the need for performing both A $\beta$ - and tau-PET in the selection process.

In light of the recently published Phase II study of donanemab in early AD,<sup>38</sup> where cognitive decline continued despite the clearance of A $\beta$  plaques as assessed by A $\beta$ -PET, it may be argued that including patients based on tau-positivity, as assessed by tau-PET, may be too late, since the treatment may not be able to halt disease progression. The parsimonious model presented in this article may, therefore, prove more suitable for anti-tau trials, acting at a later stage of disease progression.

From a clinical perspective, knowing the likelihood that a patient in the clinic will remain stable or is likely to significantly deteriorate over a relevant time interval is of great importance. "How quickly does my memory deteriorate?" was recently listed as the most important question to be answered by both AD patients and caregivers in a survey study,<sup>52</sup> followed by other questions related to cognition. Being able to address these questions is, therefore, of large interest to meet the concerns of the patients affected by the disease. By knowing the tau-PET status, the baseline performance on a few brief cognitive screening

tests, and NFL, a prediction can now be made using an easy-to-use on-line tool developed using the results of the present study (<https://brainapps.shinyapps.io/PredictMMSE/>).

There are limitations of this study. First, the follow-up period is rather short, although it is within the range of many therapeutic trials in symptomatic AD (ClinicalTrials.gov: Clarity AD, EMERGE, GRADUATE 1&2, and ENGAGE, and<sup>37–39</sup>), and represents a foreseeable time perspective from a clinical point of view. Second, the number of participants is relatively low, especially for the number of AD dementia participants, and the majority are of European descent. We cannot exclude that there may be small predictive effects seen with the non-significant biomarkers if the sample size was increased, and the results would benefit from being replicated in additional large independent cohorts. Likewise, we cannot exclude that other biomarkers may show better predictive abilities with a more diverse ethnic background. Third, MMSE may not be the optimal readout for longitudinal cognition in all settings, although it often performs well to detect decline in populations with patients with MCI or mild dementia and it is often included in clinical trials as a secondary outcome. A sensitivity analysis using a modified PACC, designed to be an earlier marker of cognitive decline, as the cognitive outcome resulted in a similar outcome compared to using longitudinal MMSE. Fourth, we aimed at making a comprehensive comparative study of biomarkers for cognitive decline in early AD, but still important biomarkers, for example, fluorodeoxyglucose (FDG)-PET, were not available in the data set and have not been included in the present study.

## 5 | CONCLUSIONS

We found that tau-PET, baseline cognition, cortical thickness, p-tau217 levels in blood and CSF, as well as CSF NFL can all individually predict future cognitive decline in patients with amnesic MCI or mild dementia. However, models including tau-PET and baseline cognition consistently provided the best prediction of cognitive decline in this heterogeneous patient population, implying that tau-PET might be an important addition to the diagnostic workup in situations where prognostic information is of importance. We further found that selecting a study population based on these biomarkers can result in a clearly reduced number of participants needed in clinical trials, for example, anti-tau trials, with cognitive decline as the primary outcome.

## ACKNOWLEDGMENTS

The authors wish to thank the participants of the study. The precursor of [18F]RO948 was kindly provided by Hoffman La Roche. Work at the authors' research center was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg Foundation (2017-0383), the Marianne and Marcus Wallenberg Foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932; AF-939981), the Swedish Brain Foundation (FO2019-0326), the Parkinson Foundation of Sweden (1280/20), the Skåne University Hospital Foundation (2020-0000028), Regionalt Forskningsstöd (2020-0314), and the Swedish Federal Government under the ALF agreement (2018-Projekt0279).

H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer's Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. K.B. is supported by the Swedish Research Council (#2017-00915); the Alzheimer's Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881), Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish Government and the County Councils; the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institutes of Health (NIH), USA (grant #1R01AG068398-01). ADNI funding: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

## CONFLICTS OF INTEREST

K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. H.Z. has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx,

and Red Abbey Labs; has given lectures in symposia sponsored by Cellectric, Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). G.K. and E.B. are both full time employees of F. Hoffmann-La Roche Ltd., Basel, Switzerland. S.P. has served on scientific advisory boards and/or given lectures in symposia sponsored by Roche, Biogen, and Geras Solutions. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau, and Roche. The other coauthors report no disclosures. Author disclosures are available in the [supporting information](#).

## REFERENCES

- Hansson O. Biomarkers for neurodegenerative diseases. *Nat Med*. 2021;27:954-963.
- Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. *Neurosci Lett*. 1999;273:5-8.
- Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Arch Gen Psychiatry*. 2012;69:98-106.
- Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol*. 2004;55:306-319.
- Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer disease. *JAMA Neurol*. 2021;78:1375-1382.
- Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. *Nature*. 2018;554:249-254.
- Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimers Dement*. 2017;13:841-849.
- Leuzy A, Chiotis K, Lemoine L, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. *Mol Psychiatry*. 2019;24:1112-1134.
- Janelidze S, Stomrud E, Smith R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. *Nat Commun*. 2020;11:1683.
- Leuzy A, Janelidze S, Mattsson-Carlsson N, et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. *Neurology*. 2021;97:e1681-e1694.
- Janelidze S, Berron D, Smith R, et al. Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. *JAMA Neurol*. 2021;78(2):149-156.
- Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nat Med*. 2020;26:379-386.
- Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol*. 2020;19:422-433.
- Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimers Dement*. 2018;14:989-997.
- Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs. other neurodegenerative disorders. *JAMA*. 2020;324:772-781.

16. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nat Med*. 2020;26:387-397.
17. Jie C, Treyer V, Schibli R, Tauvid M. The first FDA-approved PET tracer for imaging Tau pathology in Alzheimer's disease. *Pharmaceuticals (Basel)*. 2021;14:110.
18. Fleisher AS, Pontecorvo MJ. Positron emission tomography imaging with [18f]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. *JAMA Neurol*. 2020;77:829-839.
19. Smith R, Wibom M, Pawlik D, Englund E, Hansson O. Correlation of In vivo [18F]Flortaucipir with postmortem Alzheimer disease Tau pathology. *JAMA Neurol*. 2019;76:310-317.
20. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J Neuropathol Exp Neurol*. 2012;71:362-381.
21. Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between Tau, Abeta, and cortical thickness with cognition in Alzheimer disease. *Neurology*. 2019;92:e601-e612.
22. Pontecorvo MJ, Devous MD Sr, Navitsky M, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. *Brain*. 2017;140:748-763.
23. Scholl M, Lockhart SN, Schonhaut DR, et al. PET imaging of Tau deposition in the aging human brain. *Neuron*. 2016;89:971-982.
24. Aschenbrenner AJ, Gordon BA, Benzinger TLS, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. *Neurology*. 2018;91:e859-e866.
25. Pereira JB, Harrison TM, La Joie R, Baker SL, Jagust WJ. Spatial patterns of Tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. *Eur J Nucl Med Mol Imaging*. 2020;47:2155-2164.
26. Sperling RA, Mormino EC, Schultz AP, et al. The impact of amyloid-beta and Tau on prospective cognitive decline in older individuals. *Ann Neurol*. 2019;85:181-193.
27. Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol Med*. 2019;11:e11170.
28. Suarez-Calvet M, Karikari TK, Ashton NJ, et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Abeta pathology are detected. *EMBO Mol Med*. 2020;12:e12921.
29. Mattsson-Carlsson N, Andersson E, Janelidze S, et al. Abeta deposition is associated with increases in soluble and phosphorylated Tau that precede a positive Tau PET in Alzheimer's disease. *Sci Adv*. 2020;6:eaz2387.
30. Mattsson-Carlsson N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and Tau pathology and mediates the association of amyloid with Tau. *EMBO Mol Med*. 2021;13:e14022.
31. Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-Tau181 in the Alzheimer's disease neuroimaging initiative. *Mol Psychiatry*. 2021;26(2):429-442.
32. Cullen NC, Leuzy A, Palmqvist S, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. *Nature Aging*. 2021;1:114-123.
33. Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-Tau combined with other accessible measures. *Nature Medicine*. 2021;27:1034-1042.
34. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun*. 2021;12:3400.
35. Ossenkoppele R, Smith R, Mattsson-Carlsson N, et al. Accuracy of Tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. *JAMA Neurol*. 2021;78:961-971.
36. Pontecorvo MJ, Devous MD, Kennedy I, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. *Brain*. 2019;142:1723-1735.
37. Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer's disease. *N Engl J Med*. 2018;378:321-330.
38. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. *N Engl J Med*. 2021;384:1691-1704.
39. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. *Alzheimers Res Ther*. 2021;13:80.
40. Jack CR Jr, Wiste HJ, Weigand SD, Thorneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimers Dement*. 2017;13:205-216.
41. Burnham KP, Anderson DR. Multimodel inference – understanding AIC and BIC in model selection. *Sociol Method Res*. 2004;33:261-304.
42. Brier MR, Gordon B, Friedrichsen K, et al. Tau and Abeta imaging, CSF measures, and cognition in Alzheimer's disease. *Sci Transl Med*. 2016;8:338ra66.
43. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. *Neurology*. 2009;73:294-301.
44. Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. *Neurology*. 2016;87:375-383.
45. Jack CR Jr, Barnes J, Bernstein MA, et al. Magnetic resonance imaging in Alzheimer's disease neuroimaging initiative 2. *Alzheimers Dement*. 2015;11:740-756.
46. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. *Ann Neurol*. 2016;79:110-119.
47. Mattsson N, Insel PS, Donohue M, et al. Predicting diagnosis and cognition with (18)F-AV-1451 tau PET and structural MRI in Alzheimer's disease. *Alzheimers Dement*. 2019;15:570-580.
48. Risacher SL, Shen L, West JD, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. *Neurobiol Aging*. 2010;31:1401-1418.
49. Bauer CM, Cabral HJ, Killiany RJ. Multimodal discrimination between normal aging, mild cognitive impairment and Alzheimer's disease and prediction of cognitive decline. *Diagnostics (Basel)*. 2018;8:14.
50. Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. *Brain*. 2016;139:1551-1567.
51. Leuzy A, Smith R, Cullen NC, et al. Biomarker-based prediction of longitudinal Tau positron emission tomography in Alzheimer disease. *JAMA Neurol*. 2022;79(2):149-158.
52. Mank A, van Maurik IS, Bakker ED, et al. Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis. *Alzheimers Dement (N Y)*. 2021;7:e12189.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Smith R, Cullen NC, Pichet Binette A, et al. Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients. *Alzheimer's Dement*. 2023;19:2497-2507.

<https://doi.org/10.1002/alz.12875>